Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Li, Bin ^a,b   Zhang, Guangsen ^b   Li, Cui ^a   He, Dan ^a   Li, Xinying ^a   Zhang, Chunfang ^a   Tang, Faqing ^c   Deng, Xiyun ^d   Lu, Jingchen ^a   Tang, Youhong ^a   Li, Ruijuan ^b   Chen, Zhuchu ^a   Duan, Chaojun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 5; JANUS KINASE 2; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; ALPHA CYANO (3,4 DIHYDROXY) N BENZYLCINNAMIDE; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CELL GROWTH; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHIL; EOSINOPHILIC LEUKEMIA; FUSION GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; IN VITRO STUDY; MALIGNANT TRANSFORMATION; PATHOGENESIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TARGET CELL; DOWN REGULATION; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

DOWN-REGULATION; ENZYME ACTIVATION; EOSINOPHILS; HEMATOPOIETIC STEM CELLS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; JANUS KINASE 2; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 84859812498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034912     Document Type: Article

References (45)

1. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
2. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, et al. (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101: 4660-4666.
3. Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, et al. (2009) The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia 23: 271-278.
4. Gotlib J, Cools J, (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22: 1999-2010.
5. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ, (2007) Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 67: 3759-3766.
6. Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, et al. (2009) FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284: 7719-7732.
7. Ishihara K, Kitamura H, Hiraizumi K, Kaneko M, Takahashi A, et al. (2008) Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha. Biochem Biophys Res Commun 366: 1007-1011.
8. Kahn JE, Dutoit-Lefevre V, Duban-Deweer S, Chafey P, Pottiez G, et al. (2011) Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. J Proteome Res 10: 1468-1480.
9. Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, et al. (2008) Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 36: 1244-1253.
10. Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, et al. (2010) Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer 1: 346-359.
11. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, et al. (2009) Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28: 1669-1681.
12. Vassina EM, Yousefi S, Simon D, Zwicky C, Conus S, et al. (2006) cIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol 36: 1975-1984.
13. Putters J, da Silva Almeida AC, van Kerkhof P, van Rossum AG, Gracanin A, et al. (2011) Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor. PLoS One 6: e14676.
14. Hebenstreit D, Horejs-Hoeck J, Duschl A, (2005) JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 18: 243-249.
15. Lee WH, Liu FH, Lin JY, Huang SY, Lin H, et al. (2009) JAK pathway induction of c-Myc critical to IL-5 stimulation of cell proliferation and inhibition of apoptosis. J Cell Biochem 106: 929-936.
16. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, et al. (2006) The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107: 4071-4079.
17. Monahan J, Siegel N, Keith R, Caparon M, Christine L, et al. (1997) Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor. J Immunol 159: 4024-4034.
18. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
19. Chusid MJ, Dale DC, West BC, Wolff SM, (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1-27.
20. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, et al. (2004) The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 103: 2802-2805.
21. Boyum A, (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89.
22. Zhu J, Li Z, Zhang G, Meng K, Kuang W, et al. (2011) Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS One 6: e23720.
23. Strath M, Warren DJ, Sanderson CJ, (1985) Detection of eosinophils using an eosinophil peroxidase assay. Its use as an assay for eosinophil differentiation factors. J Immunol Methods 83: 209-215.
24. Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, et al. (2010) JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS One 5: e12165.
25. Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, et al. (2011) JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients. PLoS One 6: e22148.
26. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P, (2008) The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 582: 154-161.
27. Jin Y, Chen Q, Lu Z, Chen B, Pan J, (2009) Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. Cancer Sci 100: 2210-2217.
28. Pan J, Quintas-Cardama A, Manshouri T, Giles FJ, Lamb P, et al. (2007) The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 21: 1395-1404.
29. Pitini V, Arrigo C, Altavilla G, Naro C, Righi M, (2007) Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response? Leuk Res 31: 725-726.
30. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, et al. (2010) JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 24: 1069-1073.
31. Kanie T, Abe A, Matsuda T, Kuno Y, Towatari M, et al. (2004) TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways. Leukemia 18: 548-555.
32. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
33. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, et al. (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30: 965-970.
34. Burgstaller S, Kreil S, Waghorn K, Metzgeroth G, Preudhomme C, et al. (2007) The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 21: 2428-2432.
35. Burbury K, Chew LP, Westerman D, Catalano A, Seymour JF, (2011) Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. Leuk Lymphoma 52: 335-338.
36. Galimberti S, Ciabatti E, Ottimo F, Rossi A, Trombi L, et al. (2007) Cell clonality in hypereosinophilic syndrome: what pathogenetic role? Clin Exp Rheumatol 25: 17-22.
37. Yamada Y, Cancelas JA, (2010) FIP1L1/PDGFR alpha-associated systemic mastocytosis. Int Arch Allergy Immunol 152 (Suppl 1): 101-105.
38. Ip WK, Wong CK, Lam CW, (2003) Tumour necrosis factor-alpha-induced expression of intercellular adhesion molecule-1 on human eosinophilic leukaemia EoL-1 cells is mediated by the activation of nuclear factor-kappaB pathway. Clin Exp Allergy 33: 241-248.
39. Lee JS, Kim IS, (2010) Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation. Mol Biol Rep 37: 2149-2156.
40. Lee JS, Yang EJ, Kim IS, (2009) The roles of MCP-1 and protein kinase C delta activation in human eosinophilic leukemia EoL-1 cells. Cytokine 48: 186-195.
41. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, et al. (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22: 686-707.
42. Kampe M, Lampinen M, Stolt I, Janson C, Stalenheim G, et al. (2011) PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model. Inflammation.
43. Zhu Y, Bertics PJ, (2011) Chemoattractant-induced signaling via the Ras-ERK and PI3K-Akt networks, along with leukotriene C4 release, is dependent on the tyrosine kinase Lyn in IL-5- and IL-3-primed human blood eosinophils. J Immunol 186: 516-526.
44. Grivennikov SI, Karin M, (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11-19.
45. Bar-Natan M, Nelson EA, Walker SR, Kuang Y, Distel RJ, et al. (2011) Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. Leukemia.